Andere talen Sage Therapeutics, Inc.

Aandelen

SAGE

US78667J1088

Vertraagde tijd Nasdaq Andere beurzen 21:52:35 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,27 ^USD	+1,80%		-14,18%	-38,86%

18/04	SAGE THERAPEUTICS, INC. : Scotiabank handhaaft koopadvies	ZM
18/04	SAGE THERAPEUTICS, INC. : TD Cowen bevestigt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease	18/04
Top Midday Decliners	17/04
Sector Update: Health Care Stocks Advance Premarket Wednesday	17/04
Sector Update: Health Care	17/04
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	17/04
Top Premarket Decliners	17/04
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint	17/04
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	17/04
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	17/04
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	11/04
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors	26/03
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board	26/03
Sage Therapeutics to Present at Upcoming March Investor Conferences	28/02
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	14/02
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines	14/02
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/02
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M	14/02
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress	14/02
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/02
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024	31/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sage Therapeutics, Inc.

Aandelen

SAGE

US78667J1088

Andere talen

Filters